Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Foghorn Therapeutics, Inc.

Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics to Participate in the BMO Oncology Summit
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Announces CFO Departure
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Announces Chief Medical Officer Succession
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.